NCT06158984
Completed
Not Applicable
Managing Dry Eye in Patients Using Glaucoma Drops
He Eye Hospital1 site in 1 country60 target enrollmentOctober 3, 2023
ConditionsDry Eye
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Dry Eye
- Sponsor
- He Eye Hospital
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Non-invasive tear break-up time
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
A single center randomized controlled trial on managing dry eye signs and symptoms in patients using anti-glaucoma eye drops.
Detailed Description
To compare the safety and efficacy of IPL therapy on drug-induced dry eye caused by long-term use of anti glaucoma drugs;
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥18 years
- •Able and willing to comply with the treatment/follow-up schedule
- •Bilateral signs and symptoms of dry eye disease
Exclusion Criteria
- •Participants with systemic immune-mediated illnesses, such as secondary Sjögren's syndrome or graft-versus-host disease
- •Patients using topical medication(s) for the treatment of ocular disorders such as allergic conjunctivitis were excluded from the study.
- •Previous ocular surgery or trauma
- •1-month history of blepharal and periorbital skin disease or allergies
- •Severe dry eyes with corneal epithelial defect
- •Limbic keratitis
- •Pterygium
- •Corneal neovascularization
- •Breastfeeding
- •Rheumatic immune systemic diseases
Outcomes
Primary Outcomes
Non-invasive tear break-up time
Time Frame: Day-0 (baseline), 2-week, 4-weeks
Changes in non-invasive initial tear film breaking time will be assessed using the Keratograph 5M (Oculus, Germany) topographer. Three sequentially readings will be captured, and the median value will be included in the final analysis. The median value will be recorded.
Secondary Outcomes
- Quality of meibum grade(Day-0 (baseline), 2-week, 4-weeks)
- Conjunctival hyperemia (RS score)(Day-0 (baseline), 2-week, 4-weeks)
- Expressibility of meibum grade(Day-0 (baseline), 2-week, 4-weeks)
- Conjunctivocorneal epithelial staining grade(Day-0 (baseline), 1-week, 2-weeks)
- Tear Film Lipid Layer(Day-0 (baseline), 2-week, 4-weeks)
- OSDI Score(Day-0 (baseline), 2-week, 4-weeks)
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Evaluation of Dry Eye Disease's Signs in Patients Who Were Administered Intravitreal Anti-VEGF InjectionsDry Eye SyndromesNCT06317922Francesco Bandello60
Completed
Not Applicable
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse EnvironmentDry EyeDry Eye SyndromesNCT03097614Oculeve, Inc.57
Completed
Phase 4
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease PatientsDry EyeDry Eye SyndromesNCT04127851Taejoon Pharmaceutical Co., Ltd.438
Completed
Phase 3
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.Dry Eye SyndromesNCT02553772Allergan242
Completed
Not Applicable
A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual OcclusionDry EyeNCT04022382John C Meyer, MD17